Sinovac Commences Phase II Clinical Trials For Pandemic Influenza Vaccine (H5N1)

Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced that the China State Food and Drug Administration (SFDA) recently granted Sinovac approval to commence the Phase II clinical trial of Panflu(TM), a human use vaccine against the H5N1 strain of pandemic influenza virus. Panflu was jointly developed with China CDC. Two types of the H5N1 vaccine were approved by the SFDA to commence clinical trials. [click link for full article]

More: continued here

Filed under: Bird Flu on May 9th, 2007